These authors contributed equally to the work.
INTRODUCTION
HEREDITARY TYROSINEMIA TYPE I (HT1) is an autosomal recessive inborn error of metabolism of the liver caused by a deficiency in fumarylacetoacetate hydrolase (FAH), the final enzyme in the catabolism of tyrosine. The buildup of the toxic metabolites fumarylacetoacetate and succinylacetoacetate in hepatocytes leads to oxidative stress, resulting in apoptotic cell death or disrupted gene expres-sion. 1 Affecting about 1/100,000 live births worldwide, HT1 is fatal if untreated. 2 Without treatment, children present with cirrhosis, renal tubular injury, neurological crises, hepatocellular carcinoma, and, eventually, liver failure early in life. 3, 4 Liver transplant remains the only curative treatment but comes with its own difficulties, including organ shortage and the need for lifelong immunosuppression. The protective drug 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) ameliorates the disease by inhibiting an earlier enzyme in the tyrosine catabolism pathway and preventing the accumulation of toxic metabolites. When combined with a diet low in phenylalanine and tyrosine, NTBC can mitigate the need for liver transplant in 90% of cases. 2 However, even responsive patients remain at increased risk for the development of hepatocellular carcinoma and neurological degeneration. 5 The severity of these complications prompts the need for a new curative therapy beyond that of transplant.
Recent advances in gene therapy have made it possible to develop targeted treatments for a variety of disorders. Not only can gene addition therapies restore phenotype in diseases that lack a functional gene or protein product, but gene correction is becoming more precise and efficient. 6 Using a guide RNA and a Cas9 protein to induce a double-stranded break at a specific genomic target sequence, it is now possible to use CRISPR/Cas9 to produce indels through a non-homologous endjoining (NHEJ) repair pathway or to introduce a homology sequence to be incorporated via homologous recombination. 7 HT1 provides an excellent opportunity for gene therapy, as there is a strong selective advantage for corrected cells in vivo in the absence of NTBC. 8 When targeting a particular organ or cell type, ex vivo protocols-wherein cells are collected, edited, and re-transplanted-further increase the correction efficacy and safety of gene editing. 9 However, primary hepatocytes, the main cell type affected by HT1, are difficult cells to target using ex vivo gene therapy, as they are thought to be quiescent and have a limited lifespan in vitro. 10 Nevertheless, several studies have had success transducing hepatocytes ex vivo using self-inactivating lentiviral (LV) vectors, including previous work by the authors' group correcting a pig model of HT1 through an ex vivo LV gene addition protocol. [11] [12] [13] [14] LV vectors are strong candidates for gene therapy in hepatocytes, as they are known to transfect nondividing cells, have relatively safe integration profiles, and can carry large amounts of genetic information. 15 The goal of this study was to develop a targeted and effective gene-editing treatment for HT1 by delivering both the Cas9 protein and a homology template to cells ex vivo prior to transplantation. Using a LV to deliver the Cas9 gRNA and protein (herein referenced as LV-Cas9), as well as an adenoassociated virus (AAV) to deliver the homology template (AAV-HT), it was possible to demonstrate a curative ex vivo gene-correction protocol in a murine model of HT1.
MATERIALS AND METHODS

Plasmid and vector construction
Guides targeting the point mutation in the Fah gene were designed using software from Benchling.com using previously published algorithms for active guide design. 16, 17 Oligos containing BsmBI-clonable overhangs were ligated downstream of a U6 promoter in a LV vector co-expressing Cas9 (S. pyogenes) and green fluorescent protein (GFP; pL-CRISPR.EFS.GFP was a gift from Benjamin Ebert; Addgene plasmid # 57818). 18 A control single-guide RNA targeted against the LacZ gene (ACCCGAGTGTATCTGGTCGC) was also cloned into a LV expressing Cas9 (LV-LacZ). LV-Cas9 was generated and harvested using a three-plasmid construct, as described previously. 19 Vector titers, expressed in the manuscript as LV particles (LPs), were determined by p24 enzyme-linked immunosorbent assay (Clontech, Mountain View, CA).
A 1,192 base pair (bp) fragment of homology to the Fah exon 8 locus was synthesized into a gBLOCK (IDT, Coralville, IA) and cloned into an AAV vector that, after ligation, had a total length of 3,622 bp between the inverted terminal repeats. AAV-HT was created by standard triple plasmid transfection of HEK-293T cells 20 using Fugene6 (Promega, Madison, WI). Cells were incubated for 72 h and collected, and the AAV particles were purified, aliquoted, and stored at -80°C. Vectors titers were determined by quantitative polymerase chain reaction (PCR) using Luna Universal qPCR Mix (NEB, Ipswich, MA) with the following primers: 5¢-TTGCATATACGATACAAGGCTGTT, 5¢-AAAAC TGCAAACTACCCAAGAAA. Vector titers are expressed throughout as vector genome copies (GC).
Animals and animal care
All animals received humane care in compliance with the regulations of the institutional animal care and use committee at Mayo Clinic. Fah 5981SB mice, which bear a single-point mutation at the exon 8 locus as a result of N-ethyl-N-nitrosoureamediated mutation, were a generous gift from Dr. Markus Grompe (OHSU, Portland, OR). These mice are referred to as Fah -/mice throughout this article. In order to encourage positive selection for FAH+ hepatocyte proliferation, NTBC was withheld from Fah -/transplant recipient mice until they showed signs of weight decline, at which point it was administered in their drinking water at 8 mg/L for 5-7 days before it was withdrawn again.
Cell culture
In vitro experiments were conducted on Fah -/mouse fibroblasts. Fibroblast cell lines were derived from neonatal Fah -/tissue and were immortalized using a LV vector expressing the small and large SV40 T antigens. Fibroblasts were kept in Dulbecco's modified Eagle's medium (DMEM; Thermo Fisher Scientific, Waltham, MA) containing 10% heat-inactivated fetal bovine serum (FBS; Corning, Herndon, VA) and 1% penicillin/streptomycin (Corning). Cells were kept at 37°C and 5% CO 2 and were passaged using 0.05% trypsin/EDTA as needed (Thermo Fisher Scientific).
PCR and T7 endonuclease analysis
Total cells from in vitro assays were collected and processed using a DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany). For PCR amplification of uncorrected, disrupted sequence, the following two primers were used: 5¢-GGAAAGGGCTCATG TGAGTAG, 5¢-TCCATCCTTCCACTTATGAGAA. PCR conditions using Phusion polymerase (NEB) were as follows: 98°C for 3 min; 35 cycles of 98°C for 10 s, 60°C for 20 s, 72°C for 30 s; 72°C for 5min. Generated PCR products were 452 bp in length. PCR products were processed using a T7 endonuclease Alt-R Ò Genome Editing Detection Kit (Integrated DNA Technologies, Coralville, IA), electrophoresed on a 2% TAE agarose gel, and visualized with ethidium bromide staining. For selective PCR amplification of corrected sequence, the following two primers were used: 5¢-TGGAGCGGTAATGCCTCC, 5¢-AAAATGCAGGATCCACCAAG. The first primer binds selectively to the modified protospacer adjacent motif (PAM) sequence in corrected DNA, while the second binds outside of the homology template; only DNA that has successfully integrated the AAV-HT will amplify. PCR conditions were as follows: 98°C for 3 min; 35 cycles of 98°C for 10 s, 61°C for 20 s, 72°C for 45 s; 72°C for 5 min. The expected product length is 859 bp. PCR products were electrophoresed on a 2% TAE agarose gel and visualized with ethidium bromide staining.
Tracking of Indels by DEcomposition and sequencing analysis
PCR products that successfully showed sequence disruption using a T7 endonuclease assay were sequenced using Sanger sequencing. Chromatogram results were analyzed using the free online tool, Tracking of Indels by DEcomposition (TIDE). 21 This program uses decomposition algorithms in order to compare mixed pool and control chromatograms and to determine the probability of various indels in the experimental group. For next-generation sequencing (NGS) of amplicons, PCR purified products using the primers 5¢-CCAACTTTCTCCATGG CAGG and 5¢-ACCCCTGTAGTACTTAGGCC were submitted to GENEWIZ for NGS-Amplicon-EZ platform sequencing (GENEWIZ, South Plainfield, NJ).
Flow cytometry
Various AAV vector serotypes expressing GFP under control of the ubiquitous promoter cytomegalovirus (Vigene Biosciences, Rockville, MD) were transduced into primary mouse hepatocytes at a multiplicity of infection (MOI) of 50,000 GC. The medium was changed daily, and cells were analyzed for GFP expression by flow cytometry after 4 days. To dissociate cells into a single cell suspension, 0.05% Trypsin/EDTA was used. Cells were washed and fixed in 1% paraformaldehyde for 15 min prior to analysis on a FACSCalibur (BD Biosciences, San Jose, CA). Data were analyzed using FlowJo (Treestar, Ashland, OR).
Hepatocyte transplantation
Hepatocytes were harvested from an anesthetized donor mouse using a standard in situ perfusion of the liver using a mix of Collagenase NB (Serva, Heidelberg, Germany) and Thermolysin (Sigma-Aldrich, St. Louis, MO). Cell viability was determined via trypan blue exclusion assay. Cells were plated into six-well Primaria culture plates (BD Biosciences) containing the following media: DMEM, 10% FBS, 10 mM of HEPES, 10 lM of dexamethasone (Sigma-Aldrich), 7 mg/L of NTBC, 10 ng/mL of murine epidermal growth factor (Peprotech, Rocky Hill, NJ), and 1% penicillin/streptomycin. Fresh media were added 100 min later. LV-Cas9 was added at this time at the indicated MOI. AAV-HT was also added at this time at a MOI between 10,000 and 20,000, as indicated. Twentyfour hours post transduction, Hepatocytes were harvested with 0.05% trypsin/EDTA, centrifuged, and re-suspended for transplantation in 200 lL of media containing 2 lg/mL of DNaseI (Sigma-Aldrich). The cells were then injected into recipient mice via intra-splenic injection, as described previously. 22 A two-thirds partial hepatectomy was performed on one cohort of mice, as previously described. 23 
Histology and biochemical analysis
For histological analysis, tissue samples were fixed in 10% neutral-buffered formalin (Protocol; Thermo Fisher Scientific, Pittsburgh, PA) and processed for paraffin embedding and sectioning. For hematoxylin and eosin (H&E) staining, slides were prepared with standard protocols. A blinded histopathological analysis was performed by a trained veterinarian pathologist. FAH immunohistochemistry using a polyclonal rabbit anti-FAH primary antibody 24 was performed with a Bond III automatic stainer (Leica, Buffalo Grove, IL) with a 20 min antigen retrieval step using Bond Epitope Retrieval Solution 2 (Leica), and stained with diaminobenzidine (Leica). GFP immunohistochemistry using a monoclonal rabbit anti-GFP primary antibody (GFP #2956; Cell Signaling Technology, Danvers, MA) was also performed with a Bond III automatic stainer with a 20 min antigen retrieval step using Bond Epitope Retrieval Solution 2, and stained with diaminobenzidine. For biochemical analysis of alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin, and total bilirubin (TBIL), plasma was analyzed with the VetScan VS2 benchtop analyzer (Mammalian Liver Profile; Abaxis, Union City, CA) according to the manufacturer's instructions. Tyrosine values were determined using tandem mass spectrometry and chromatography via Mayo Clinic's internal biochemical PKU test. Quantification of FAH-positive cells was obtained using a cytoplasmic stain algorithm in Aperio ImageScope. Fifteen rectangular areas totaling 954,829.4 lm 2 were randomly selected and analyzed. Reported results are total percentage of cytoplasmic FAH positivity among the cells selected.
Statistical analysis
Data were analyzed using GraphPad Prism v7 (GraphPad Software, Inc., San Diego, CA). Variances were determined by the F-test. Experimental groups with equal variances were compared using an unpaired two-tailed Student's t-test. Experimental groups with unequal variances were compared using a two-tailed Welch's t-test. Differences between multiple groups were compared using one-way analysis of variance followed by Tukey's multiple comparisons test. Due to the inability to keep untreated Fah -/mice alive off of NTBC for the duration of the experiment, historical controls were used for the plasma data at time of sacrifice. A p-value of <0.05 was considered statistically significant.
RESULTS
LV-Cas9.sgFah can robustly edit Fah -/cells at the target locus
For this series of experiments, Fah -/cells from a mouse model of HT1 were utilized. These Fah -/mice carry a G / A point mutation in the last nucleotide of exon 8 (Fig. 1A) , leading to a splicing defect and a truncated, unstable, and nonfunctioning FAH protein. 25 A single LV vector was generated that expressed S. pyogenes Cas9 nuclease and a guide RNA targeted to the point mutation surrounding exon 8 of the Fah gene (LV-Cas9; Fig. 1C ). Fibroblasts from Fah -/mice were transduced to determine the efficiency and spectrum of mutations caused by CRISPR/Cas9 at the targeted locus using LV-Cas9. Generation of double-strand breaks was confirmed by T7 endonuclease analysis ( Fig. 2A) . As expected, a range of mutations were identified using both NGS of amplicons and TIDE analyses of Sanger sequencing results ( Fig. 2B and C) .
Correction of Fah using AAV is dependent on CRISPR/Cas9
Initially, a pilot experiment was performed in primary mouse hepatocytes to determine the efficiency of common AAV serotypes to transduce hepatocytes. Using a GFP vector, the serotypes 2 and DJ gave significantly better transduction than (Fig. 3A) . Based on these data, and previous use of the DJ serotype to perform gene editing in pig fibroblasts for somatic cell nuclear transfer, 26 the DJ serotype was utilized for the remainder of the experiments. The AAVtargeting vector contained approximately 1.2 kb of homology that contained the correct G for proper Fah splicing, in addition to a modified sequence downstream of the corrected point mutation that would disrupt future cutting at the target site by modifying the PAM sequence (Fig. 1B) . The hypothesis was tested that Cas9 expression is critical for gene correction at the Fah locus by comparing gene correction in the presence of AAV-HT alone or combined with LV-Cas9 (with a sgRNA Fah guide) or with LV-LacZ (a control sgRNA targeted against the LacZ gene; Fig. 3B ). A positive PCR signal was only detected in cells receiving both LV-Cas9 against Fah and AAV-HT. Next, Fah -/fibro-blasts were transduced with various MOIs of AAV with or without LV-Cas9. After 72 h, PCR analysis using specific primers that can only amplify repaired Fah confirmed correction of the target site at various MOIs of AAV (Fig. 3C ).
Transplantation of gene-edited hepatocytes can prevent liver failure in Fah -/mice
Previous work with primary hepatocytes identified optimal conditions for high transduction with VSV-G-pseudotyped LV vectors. 27 Using these culture conditions, hepatocytes from a donor Fah -/mouse were isolated and cultured for <24 h in the presence of LV-Cas9 and AAV-HT. Hepatocytes were harvested and transplanted into syngeneic Fah -/mice by intra-splenic injection. One group of recipient mice received a two-thirds partial hepatectomy immediately prior to transplantation to investigate whether regenerative cues would improve gene repair and proliferation in vivo (Fig. 4A) . Recipient mice were cycled on/off NTBC to stimulate expansion of corrected hepatocytes in vivo. Interestingly, while both groups of animals became weight stable off NTBC (Fig. 4B) , mice that received a partial hepatectomy became weight stable significantly sooner than animals that only received hepatocyte injections (Fig. 4C ).
Transplantation of gene-edited hepatocytes can cure metabolic disease
Six months after transplantation, all mice were euthanized, and a thorough analysis of biochemical and histological markers of disease was performed.
As expected based on the weight data, all mice had significant reductions in biochemical makers of liver injury, including ALT, AST, ALP, and TBIL (Fig. 5) . Albumin levels were also significantly higher in transplanted mice compared to controls. Specific to HT1, tyrosine levels in the blood were reduced to normal levels, indicating complete amelioration of aberrant tyrosine catabolism in these mice. Next, the histology of the livers was analyzed using FAH ( Fig. 6A and Supplementary  Fig. S1 ; Supplementary Data are available online at www.liebertpub.com/hum), GFP (co-expressed with Cas9 by the LV; Supplementary Fig. S2 ), and H&E (Fig. 6A ). All mice displayed significant re- population of the Fah -/mouse liver with corrected hepatocytes, as indicated by FAH staining. In congruence with the weight data, mice that received partial hepatectomy had significantly increased numbers of FAH+ cells, as determined by digital quantification of FAH+ cells in transplanted livers (Fig. 6B ). Finally, using NGS of amplicons, the molecular status of the corrected allele was characterized in all six mice (Fig. 6C) . The mean percentage of corrected alleles in transplanted mice was calculated to be 21.7%. Based on the hepatocyte cell number in the liver and the natural polyploidy status of hepatocytes, these data correlate with the FAH histology showing robust hepatocyte expansion of corrected cells in vivo. Interestingly, a number of other mutations were also detected at high frequency at the edited locus, indicating the potential for CRISPR/ Cas9 to cause unwanted changes in the genome when delivered by integrating vectors (Fig. 6C) .
DISCUSSION
This study aimed to genetically edit and phenotypically cure a mouse model of HT1 through the use of a viral vector-delivered Cas9 protein and homology template using an ex vivo protocol. After delivering the LV-Cas9 and the AAV-HT to purified hepatocytes and transplanting them via intra-splenic injection, recipient mice were cycled on and off NTBC to encourage proliferation of corrected cells until NTBC-independent weight gain was achieved. As shown by weight profiles, biochemical data, and histological imaging, the treatment was successful, demonstrating for the first time proof-of-concept for ex vivo hepatocyte-directed gene editing using CRISPR/Cas9.
Although allogeneic hepatocyte transplantation has demonstrated safety and partial efficacy in preclinical and clinical settings, its widespread use is severely limited by a shortage of donor hepatocytes and the immune response against the allogeneic cells. 28, 29 Ex vivo autologous hepatocyte-directed gene therapy using integrating vectors has been previously demonstrated in small-and largeanimal models of metabolic liver disease. Initially utilizing gamma retroviral vectors to deliver and integrate the missing gene randomly into the host genome, a number of preclinical studies demonstrated efficacy of an ex vivo approach for metabolic liver diseases. [30] [31] [32] [33] These preliminary data were sufficient for a clinical trial to occur in five patients with familial hypercholesterolemia in which a gamma-retroviral vector containing the LDLR gene was delivered to cultured hepatocytes after resection, and transduced autologous cells were re-transplanted. 34, 35 While only some therapeutic efficacy was shown, this important study provided clinical proof-of-concept for future ex vivo hepatocytedirected gene therapy approaches. With the advent of self-inactivating LV vectors, and their encouraging success in clinical trials with hematopoietic stem cells for treating primary immunodeficiencies, 36 ,37 a number of preclinical studies have shown that ex vivo transduction of primary hepatocytes with LV vectors can ameliorate metabolic liver disease in rodent and pig models. 38, 39 Therefore, this group of studies provided the foundation to continue to pursue the development of ex vivo hepatocyte-directed CRISPR/Cas9-mediated gene therapy as an alternative to orthotopic liver transplantation for metabolic liver disease.
The advent of precision gene editing has changed the landscape for hepatocyte-directed gene therapy. A number of elegant studies have demonstrated the potential for in vivo delivery of endonucleases, including zinc finger nucleases and CRISPR/Cas9, combined with delivery of a repair template, to correct and cure disease in rodent models. [40] [41] [42] [43] While an in vivo approach to liver gene therapy is attractive for a number of reasons, ex vivo gene therapy provides many advantages for liver-directed gene therapy. First, the source of autologous cells is inherent in the therapy, and in addition to providing cells by means of liver resection, the procedure is strongly pro-regenerative, 44 therefore providing a stimulus for transplanted cells to proliferate. Second, in contrast to an in vivo approach, this therapeutic method ensures specific targeting of the intended cell type-the hepatocyte-at much lower and safer vector doses than are needed with systemic administration of viral vectors. Third, although much more research is needed to make this feasible, ex vivo gene therapy opens up the possibility of correcting and expanding hepatocytes ex vivo, prior to re-transplantation into the patient. 45 To the authors' knowledge, this study is the first to demonstrate the efficacy of combining CRISPR/ Cas9-mediated gene editing and hepatocyte transplantation together to cure a metabolic liver disease. However, a number of challenges will need to be overcome prior to bringing this novel regenerative therapy to the clinic for the many metabolic liver diseases. First, the use of a LV vector to express the Cas9 and guide RNA would not be the optimal method to deliver these gene-editing components due to the risk of continued Cas9-mediated off-target gene editing. The present data demonstrate continued expression of GFP, which is coexpressed with Cas9, 6 months after transplantation. Therefore, future ex vivo gene-editing approaches should focus on the use of other nonintegrating viral vectors (e.g., AAV) or, even preferably, the use of non-viral vectors for shortterm expression of Cas9. Second, hepatocyte gene editing provides the formidable obstacle of cells not actively replicating and therefore predominantly repairing DNA damage of double-strand breaks by NHEJ. This obstacle has been previously highlighted with recent in vivo gene-editing approaches, with DNA repair efficiencies significantly lower in adult mice compared to neonatal mice. 43 A partial hepatectomy was utilized as a clinically relevant method to improve gene editing in transplanted hepatocytes. 29 Further work is needed to evaluate the therapeutic benefit of this approach in other models. Other methods that either stimulate hepatocyte replication or provide a selective advantage for transplanted hepatocyte proliferation 46 could also be optimized for efficient gene editing in adult hepatocytes to occur. Third, while the Fah -/mouse model provides an excellent proof-of-concept for gene-editing studies, the robustness and clinical relevance of ex vivo gene editing will need to be demonstrated in other models. The Fah -/mouse model provides a massive repopulation advantage for FAH+ cells over host FAH-cells; previous studies have shown that as few as 1,000 FAH+ hepatocytes can correct metabolic deficiency in Fah -/mice. 8 Therefore, while other metabolic diseases may also provide some selective advantage for corrected cells (most notably alpha-1 antitrypsin deficiency 47, 48 ) improved gene-editing protocols will need to be optimized for this novel therapeutic strategy to be applied to other metabolic diseases where no apparent repopulation advantage is present. Finally, future work is needed to evaluate the ability of AAV to mediate robust gene editing in the absence of CRISPR/Cas9. The molecular status of cells ex vivo ( Fig. 3B ) and after 6 months in vivo (Fig. 6C ) indicated significant indels at the Fah locus produced by CRISPR/Cas9. Further studies are needed to evaluate the ontarget as well as off-target effects of CRISPR/Cas9, particularly in the context of an integrating vector.
In summary, the present data provide proof-ofconcept for the application of hepatocyte-directed CRISPR/Cas9-mediated gene editing to metabolic liver diseases. The results demonstrated curative gene and cell therapy in a mouse model of HT1. Future work is needed to optimize this novel therapeutic approach, but these results lay the foundation for future endeavors to bring this therapy to the clinic for patients with metabolic liver disease who are currently only curable by whole-organ transplantation. In much the same way as has been demonstrated for patients with primary immunodeficiencies, 36, 37, 49 the potential for autologous gene therapy-using partial hepatectomy to isolate hepatocytes-is envisioned to be an alternative regenerative therapy for patients with metabolic liver disease.
